ProKidney Management
Management criteria checks 4/4
ProKidney's CEO is Bruce Culleton, appointed in Nov 2023, has a tenure of 2.08 years. total yearly compensation is $1.02M, comprised of 61.5% salary and 38.5% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth $7.76M. The average tenure of the management team and the board of directors is 2 years and 3.7 years respectively.
Key information
Bruce Culleton
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 61.53% |
| CEO tenure | 2.1yrs |
| CEO ownership | 1.1% |
| Management average tenure | 2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation
Mar 03
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Jan 31We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
Nov 18We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
Aug 12We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth
May 12Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
Nov 17ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business
Mar 14ProKidney reports Q2 2022 results
Aug 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$71m |
| Jun 30 2025 | n/a | n/a | -US$72m |
| Mar 31 2025 | n/a | n/a | -US$68m |
| Dec 31 2024 | US$1m | US$625k | -US$61m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$35m |
| Dec 31 2023 | US$9m | US$245k | -US$35m |
Compensation vs Market: Bruce's total compensation ($USD1.02M) is below average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
CEO
Bruce Culleton (57 yo)
Dr. Bruce Culleton, M.D., is Chief Executive Officer and Director at ProKidney Corp. since November 15, 2023. He was Executive Vice President of Clinical Development & Commercialization of ProKidney Corp....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$1.02m | 1.09% $ 7.8m | |
| EVP of Science and Technology | 1.1yrs | US$1.29m | 0% $ 0 | |
| Chief Legal Officer & Secretary | 3.8yrs | US$1.26m | 0.12% $ 827.0k | |
| Chief Financial Officer | 3.9yrs | US$2.29m | 0% $ 0 | |
| Senior VP of Manufacturing & Operations | 1.9yrs | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Chief People Officer | 1.6yrs | no data | no data | |
| SVP of Clinical Affairs | 6.2yrs | no data | no data | |
| Chief Reg. Off | 5.3yrs | no data | 0% $ 0 | |
| Chief Business Officer | 2.1yrs | no data | no data | |
| Senior VP of Biometric | 2yrs | no data | no data | |
| Senior Vice President of Global Clinical Operations | 1.9yrs | no data | no data |
Experienced Management: PROK's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$1.02m | 1.09% $ 7.8m | |
| Lead Independent Director | 3.9yrs | US$243.14k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$260.82k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$252.89k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$253.89k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$239.39k | 0.021% $ 151.4k | |
| Chairman of the Board | no data | US$264.39k | 15.98% $ 114.2m | |
| Independent Director | no data | US$233.39k | 0% $ 0 |
Experienced Board: PROK's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 11:34 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProKidney Corp. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Vamil Divan | Guggenheim Securities, LLC |